BioSante Pharmaceuticals, Inc. (AMEX:BPA) reported product development highlights
and financial results for the third quarter ended September 30, 2005. "We
achieved milestones across our key clinical programs this quarter. We presented
positive Phase III data for Bio-E-Gel(TM), licensed three patents that cover
the use of testosterone (LibiGel(TM)) to treat hypoactive sexual desire disorder
in women on hormone contraception, and entered into an allergy licensing option
agreement for our CaP nanotechnology," said Stephen M. Simes, BioSante's
president and chief executive officer.